Skip to Content

Generic Afinitor Disperz Availability

See also: Generic Afinitor

Afinitor Disperz is a brand name of everolimus, approved by the FDA in the following formulation(s):

AFINITOR DISPERZ (everolimus - tablet, for suspension;oral)

  • Manufacturer: NOVARTIS PHARM
    Approval date: August 29, 2012
    Strength(s): 2MG [RLD], 3MG [RLD], 5MG [RLD]

Has a generic version of Afinitor Disperz been approved?

No. There is currently no therapeutically equivalent version of Afinitor Disperz available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Afinitor Disperz. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
    Patent 5,665,772
    Issued: September 9, 1997
    Inventor(s): Cottens; Sylvain & Sedrani; Richard
    Assignee(s): Sandoz Ltd.
    Novel derivatives of rapamycin, particularly 9-deoxorapamycins, 26-dihydro-rapamycins, and 40-0-substituted and 28,40-0,0-di-substituted rapamycins, are found to have pharmaceutical utility, particularly as an immunosuppressants.
    Patent expiration dates:
    • September 9, 2019
      Drug substance
      Drug product
    • March 9, 2020
      Pediatric exclusivity
  • Macrolides
    Patent 7,297,703
    Issued: November 20, 2007
    Inventor(s): Navarro; Francois & Petit; Samuel & Stone; Guy
    Assignee(s): Novartis AG
    A mixture comprising a poly-ene macrolide and an antioxidant. Preferably, the poly-ene macrolide is rapamycin and the antioxidant is 2, 6-di-tert.-butyl-4-methylphenol. The presence of the antioxidant improves the stability of the poly-ene macrolide to oxidation.
    Patent expiration dates:
    • December 6, 2019
      Drug product
    • June 6, 2020
      Pediatric exclusivity
  • Pharmaceutical compositions comprising colloidal silicon dioxide
    Patent 8,617,598
    Issued: December 31, 2013
    Assignee(s): Novartis AG
    A pharmaceutical composition comprising a macrolide solid dispersion, a disintegrant and colloidal silicon dioxide, wherein the composition comprises 1 to 5% colloidal silicon dioxide by weight.
    Patent expiration dates:
    • September 27, 2022
      Drug product
    • March 27, 2023
      Pediatric exclusivity
  • Treatment of solid tumors with rapamycin derivatives
    Patent 8,778,962
    Issued: July 15, 2014
    Assignee(s): Novartis Pharmaceuticals Corporation
    Rapamycin derivatives have interesting effects in the treatment of solid tumours, optionally in combination with a chemotherapeutic agent.
    Patent expiration dates:
    • February 18, 2022
    • August 18, 2022
      Pediatric exclusivity

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • April 29, 2018 - PEDIATRIC EXCLUSIVITY
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.